Payers want pharma to address the challenges they face Specialised cancer therapies such as checkpoint inhibitors have significantly improved outcomes for patients—but for payers they represent a growing pricing and reimbursement (P&R) challenge, especially as triple and quadruple oncology […]
Digital Technologies: New Strategies for Customer Engagement
Digital technology and tools have changed the landscape for customer engagement beyond recognition. The possibilities for targeted interactions, relationship building and adding value are immense—and the insights revealed through data generation and analysis can really build competitive advantage. […]
Real World Evidence (RWE) Solutions Market by Component, Application, End User – Global Forecast to 2024
The real-world evidence (RWE) solutions market is expected to grow at a CAGR of 15% from 2019 to reach $1.64 billion by 2024. The researchers believe that explosive growth will be driven by a variety of factors. These include rising geriatric population and burden of chronic diseases, the shift […]
2019 Healthcare Benchmarks: Social Determinants of Health
2019 Healthcare Benchmarks: Social Determinants of Health is the second comprehensive analysis by the Healthcare Intelligence Network of programs aimed at addressing social determinants of health (SDOH), including populations prioritized for SDOH screening, preferred screening tools, interventions, […]
Pricing Transparency in Pharma
Pricing transparency is an issue that will not got away and pharma must actively engage if it is to influence the debate. That is why in Pricing Transparency in Pharma we interviewed experts to help you understand the current drive for price transparency, the countries and organisations leading the […]
Medical Affairs: The Roadmap to 2025
The current report provides details the significance of medical affairs functional area in the pharmaceutical industry supported ’s expert insights. A detailed analysis on the current scenario, structure, cross-functioning role and importance of medical affairs is provided in the report. The […]
Health Economics & Outcomes Research (HEOR) Services Market Share & Forecast, 2020–2026
Global Market Insights, Inc. has recently added a new report on health economics and outcomes research services market which estimates the global market valuation for HEOR services will cross US$ 1.7 billion by 2026. The market growth is attributed to increasing prevalence of chronic diseases and […]
Pharmaceutical Payment System Market – Quantitative Analysis, Current and Future Trends, 2020 – 2027
The Global Pharmaceutical Payment System Market 2020 Research Report is a professional and in-depth study on the current state of the Pharmaceutical Payment System Market industry. Global Pharmaceutical Payment System Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts up to […]
The Future of Personalised Medicine: The Role of Simulation and Digital Twins
There is considerable excitement about the potential for simulation and digital twin technology to drive the personalised health agenda through better diagnosis of disease, faster and cheaper clinical trials and better training and engagement with physicians. Overcoming the considerable technical, […]
Medical Diagnostics: leveraging new opportunities from AI driven technology
Artificial intelligence (AI) driven technologies have already revolutionized practice and outcomes in medical imaging and pathology—so where next for this disruptive technology? Artificial intelligence may help accurately diagnose and treat diseases, improve patient experience, facilitate medical […]
Massive Growth in Digital Health Technology Market by Athenahealth, McKesson Corporation, Qualcomm, LifeWatch, AT & T, Cerner Corporation, Philips Healthcare, Cisco Systems
The Research Insights has published an analytical study titled as global Digital Health Technology Market. This statistical data focuses on the performance of both historical records along with the recent trends. It includes a complete analysis of different attributes such as manufacturing base, […]
Real World Evidence: The Role of Medical Affairs
The RWE team may have begun as an 'add-on' to medical affairs in response to the big data revolution but its role and importance has grown significantly. Reams of data are now transformed into powerful insight that drives decision-making. And as RWE is now embedded into medical affairs activities, […]
Pharmacy Benefit Management (PBM) – Industry Size 2019, Market Opportunities, Share Analysis up to 2025
New 2019 Report on “Pharmacy Benefit Management (PBM) Market size | Industry Segment by Applications (Retail or Mail-Order Pharmacies, Specialty Pharmacies and Online Pharmacies), by Type (Network-Pharmacy Claims Processing, Home Delivery Pharmacy Care, Specialty Pharmacy Care, Specialty Benefit […]
Democrats and Drug Pricing
Consider this your insider's guide to the 2020 Democratic candidates and their plans to overhaul the drug industry. From the mildest moderates to the staunchest progressives, nearly every Democrat seeking the party’s nomination for president next year has made drug pricing a central element of his […]
Global Health Economics & Outcomes Research (HEOR) Services Market Size, Share, Growth, Status and Forecast 2019-2025
This report focuses on the global top key players: IQVIA, Pharmaceutical Product Development (PPD), RTI Health Solutions, UnitedHealth Group, Laboratory Corporation of America The report then estimates 2019-2025 market development trends of Health Economics & Outcomes Research (HEOR) Services […]
Global Value-Based Reimbursement Software Market Size, Status and Forecast to 2026
Demand and Growth of Value-Based Reimbursement Software Market 2019 Segmentation, Technological Advancement, SWOT Analysis, Future Growth & Forecast to 2026, Focusing on top key players like iClinic, HealthQx, Quadax, 3M Codefinder, AccuReg, ActiveASSIST, Apex Connect and others IT […]
Benchmarking Key Account Management Capabilities (2019)
What factors determine a Key Account Manager (KAM) team's size and structure? At what stage in a product's lifecycle are KAMs assigned and how many brands should a typical KAM support? What personal attributes and knowledge are seen as essential to successfully fulfilling a KAM role? What […]
The Future of Key Account Management in Pharma
While the Key Account Management (KAM) role will continue to prioritise the development of long-term, sustainable partnerships between pharmaceutical vendors and healthcare providers, the evolution of these relationships, and the techniques and policies which drive practice, are set for radical […]
Indication-level Pricing: Payer Insights
Advocates argue that indication-level pricing can bring new products on stream and results in wider patient access to new therapies. That's a good thing, right? Maybe, but for indication-level pricing to work payers would have to overcome a range of practical and costly administrative, data […]
Real-World Data Capabilities: Benchmarking Pharma Companies (2019)
The impact of real-world data (RWD) is growing but few companies are fully exploiting its potential across all clinical and commercial areas. While most companies are focusing their RWD efforts towards meeting the evidence requirements of payers, RWD is also being used to define clinical research […]
Success in Managed Markets: Payer Insights
US expenditure (per capita) on prescription drugs is at an all time high and showing no signs of reversing - so, it's understandable that payers are totally focused on value. But when 'value' means different things to payers and manufacturers sitting on opposite sides of the negotiating table, how […]
Real World Data and Evidence: Payer Insights
It's sink or swim time. Advancements in drug data collection methodologies and deeper understanding of what can be achieved has finally opened the floodgates on real world data (RWD). Information is coming onstream thick and fast and pharma can either become disoriented or use it to drive forward […]
KAM Metrics: Measuring Success (2019)
KAM teams are still evolving but they're also concerned about their future. They need appropriate measures to demonstrate their true value because without them, it's impossible to understand the real impact of their specialist skills. It's widely agreed that both quantitative and qualitative tools […]
Biomarkers and Companion diagnostics: Payer Insights
The investment decisions made by the biggest players in core disease areas drive market trends—so it's crucial to understand where the big money is going and why. And as advancements in technology as well as business forces are inspiring fresh thinking in R&D, data, systems and commercial […]
Paying for Digital Health: Payer Insights (2019)
How and where can digital health technology improve patient outcomes and save payers money? Across the digital health field there are hundreds of applications available but how many really meet a clinical need, lead to a positive and provable outcome, and can practically fit into a physician's […]
Biosimilars: U.S. Market Analysis, Insights and Forecast, 2019-2026
The U.S. Biosimilars Market will gain momentum from the increasing government support to adopt biosimilars in the healthcare sectors. According to a report by Fortune Business Insights, titled, "Biosimilars: U.S. Market Analysis, Insights and Forecast, 2019-2026," the U.S. biosimilars market is […]
Biosimilars: US Payer Insights (2019)
How do payers view the trends in the sluggish US biosimilar market and what initiatives do they want from pharma? Originator companies are fiercely defending their brands which has slowed new product introductions and limited clinicians' ability to build prescribing confidence with biosimilar […]
Review of Influence: The Institute for Clinical and Economic Review
The ICER's novel and inclusive work on the value of drugs, using its own value framework and assessing the affordability, and even going so far as setting the value-based price benchmark of new drugs, has given payers powerful negotiating tools. The impact on pricing is being felt while drug […]
Innovative Drugs: Mapping the Pricing and Reimbursement Landscape
Health Technology Assessment (HTA) reviews are shaping the competitive landscape for innovative drugs in non-US markets. Between January 2016 and June 2018, 95 innovative medicines were approved in the U.S. – but only 67 have launched in a major market elsewhere. Understanding which companies and […]
Orphan Drugs: European Payer Perspectives
European payers are concerned about orphan drugs citing unjustified high prices and a lack of evidence of utility and value. Pharma has a trust issue with payers, so how can the industry get back on track and gain European payer support for the expanding orphan drug sector? Payers may have concerns […]
